Vaxart, Inc.
Vaxart, Inc.
Your view on VXRT
Overview
What the company does, where it operates, and who runs it.
About Vaxart, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven Lo
- Headquarters
- 170 Harbor Way, South San Francisco, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven Lo
- Headquarters
- 170 Harbor Way, South San Francisco, CA, US
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.
The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.
4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.
It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Vaxart, Inc. from FRC's valuation model, read against the market price. VXRT last traded at $0.53, 3.0× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Vaxart, Inc.. Starting points for Vaxart, Inc.: P/E 3.0, EPS $0.12, beta 1.09 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Vaxart, Inc.. Vaxart, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Vaxart, Inc.. Trailing twelve-month EPS for Vaxart, Inc. stands at $0.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$2.00
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | $0.04 | -$0.05 | -$0.42 |
| Low estimate | $0.04 | -$0.05 | -$0.42 |
| High estimate | $0.04 | -$0.05 | -$0.42 |
| No. of analysts | 1 | 1 | 1 |
| Year-ago EPS | -$0.111 | $0.071 | — |
| Growth | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | $41.60M | $118.60M | $2.35M |
| Low estimate | $41.60M | $118.60M | $2.35M |
| High estimate | $41.60M | $118.60M | $2.35M |
| No. of analysts | 1 | 1 | 1 |
| Year-ago revenue | $104.24M | $237.26M | — |
| Growth | -60.1% | -50.0% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Vaxart, Inc.. Vaxart, Inc. has reported as a listed company since 1981. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ARCTArcturus Therapeutics Holdings Inc.Biotechnology$240M
- BVNRYBavarian Nordic A/SBiotechnology$2.4B
- GOVXGeoVax Labs, Inc.Biotechnology$850,325
- INOInovio Pharmaceuticals, Inc.Biotechnology$97M
- MRNAModerna, Inc.Biotechnology$87.1B
- NVAXNovavax, Inc.Biotechnology$1.3B
- OCGNOcugen, Inc.Biotechnology$262M
- PCVXVaxcyte, Inc.Biotechnology$9.8B
More Biotechnology companies
- GLMDGalmed Pharmaceuticals Ltd.NASDAQ$5M
- GLOW.CNGlow Lifetech Corp.CNQ$11M
- GLPGFGalapagos N.V.OTC$2.2B
- GLSHQGelesis Holdings, Inc.OTC$7,334
- DBVTDBV Technologies S.A.NASDAQ$246M
- DFTXDefinium Therapeutics, Inc.NASDAQ$4.1B
- DMACDiaMedica Therapeutics Inc.NASDAQ$449M
- DMED.CNDiagnamed Holdings Corp.CNQ$6M
- DMRADamora Therapeutics, Inc.NASDAQ$1.4B
- DMTRF3-D Matrix, Ltd.OTC$285M
- DNAGinkgo Bioworks Holdings, Inc.NYSE$551M
- DNAGDNAPrint Genomics, Inc.OTC$6,446
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Vaxart, Inc., and how their positions are changing. At a $129.3M market value, institutional positions materially move Vaxart, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Vaxart, Inc. executives and directors. Shares of Vaxart, Inc. have traded between $0.26 and $0.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Vaxart, Inc.. Coverage tracks Vaxart, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Vaxart, Inc.